$0.95
0.91% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US59503A1051
Symbol
MBOT
Sector
Industry

Microbot Medical Inc Stock News

Neutral
GlobeNewsWire
19 days ago
U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it has successfully completed enrollment and follow up for all patient...
Neutral
GlobeNewsWire
about one month ago
Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study BRAINTREE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it is currently experiencing an acce...
Neutral
GlobeNewsWire
about 2 months ago
Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024 Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024
Neutral
GlobeNewsWire
2 months ago
The agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform
Neutral
GlobeNewsWire
3 months ago
The ISO 13485 certification is a validation of the Company's robust quality system The ISO 13485 certification is a validation of the Company's robust quality system
Neutral
GlobeNewsWire
3 months ago
The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system
Neutral
GlobeNewsWire
4 months ago
As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women's Hospital and Baptist Hospital of Miami as sites for the pivotal human clinical trial As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women's Hospital and Baptist Hospital of Miami as sites for the pivotal human clinical trial
Neutral
GlobeNewsWire
4 months ago
Baptist Hospital of Miami is the second site to perform clinical procedures as part of the Company's Pivotal Human Clinical Trial.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today